Compare Dropbox Inc (DBX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Mesoblast Limited — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Dropbox Inc is far larger — about 4.1× Mesoblast Limited's market cap, and Dropbox Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Mesoblast Limited for 14 Days on average.
| DBX | MESO | |
|---|---|---|
Market Cap | $7.42B | $1.81B |
Volume | 3,061,580 | 240,620 |
Sector | Technology | Health |
52-Week High | $37.74 | $20.96 |
52-Week Low | $22.06 | $13.19 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $10.29B | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% today, showing bearish technical signals with resistance at $34. Fundamentally, the company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights insider selling and a security breach affecting 5,000 accounts in August 2026, while analyst sentiment remains divided with a consensus price target of $26.83.
The outlook remains cautious due to mixed analyst ratings and insider selling activity. While strong cash flow generation and consistent earnings beats provide support, valuation concerns and stagnant revenue growth near $2.5B present headwinds. Key risks include competitive pressures in cloud storage and execution challenges in maintaining market position.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
